AEON Biopharma, Inc.
AEON evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AEON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AEON
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing its sole product candidate, ABP-450, a botulinum toxin formulation for therapeutic indications, and has never generated revenue from product sales.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for AEON Biopharma, Inc..
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing its sole product candidate, ABP-450, a botulinum toxin formulation for therapeutic indications, and has never generated revenue from product sales.
- AEON Biopharma's sole product candidate is ABP-450, a botulinum toxin formulation being developed for therapeutic indications [sec · filed 2025-12-29].
- The company has never been profitable from operations and, as of March 31, 2026, had an accumulated deficit of $482.6 million [sec_mda · as of 2026-05-14].
- As of June 30, 2026, AEON reported cash and cash equivalents of $3.4 million and shareholders' equity of -$55.0 million [sec].
- Management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing [sec_mda · as of 2026-05-14].
- AEON expects to have sufficient cash to fund operations into the third quarter of 2026, including funds received from a second closing [sec_mda · as of 2026-05-14].
What works
- AEON is pursuing a Section 351(k) biosimilar pathway for ABP-450, which could potentially offer a more streamlined regulatory path [sec · filed 2025-12-29].
- The company has engaged in a Biological Product Development meeting with regulators, indicating active dialogue on development strategy [sec · filed 2025-12-29].
What to weigh
- AEON has never generated revenue from ABP-450 and has a history of significant operating losses and negative cash flows [sec_mda · as of 2026-05-14].
- The company faces substantial doubt about its ability to continue as a going concern, with cash runway only into Q3 2026 [sec_mda · as of 2026-05-14].
- Any further development of ABP-450 will require additional funding, which may not be available on reasonable terms or at all [sec_mda · as of 2026-08-12].
- AEON's accumulated deficit has grown to $482.6 million as of March 31, 2026, reflecting years of R&D and operational spending without product revenue [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
AEON has never generated revenue from its product candidate ABP-450.
“We have never generated revenue from ABP-450.”
SEC filings · December 29, 2025
The company has an accumulated deficit of $482.6 million as of March 31, 2026.
“as of March 31, 2026, we had an accumulated deficit of $482.6 million.”
SEC MD&A · May 14, 2026
Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
“We have concluded that we do not have sufficient cash to fund our operations for 12 months from the date of our financial statements without additional financing, and as a result, there is substantial doubt about our ability to continue as a going concern.”
SEC filings · May 14, 2026
AEON expects cash runway into the third quarter of 2026.
“As of the date of this Report, we expect to have sufficient cash to fund our operating plan into the third quarter of 2026, including funds of $4.2 million received from the Second Closing.”
SEC MD&A · May 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has substantial doubt about the company's ability to continue as a going concern without additional financing [sec_mda · as of 2026-05-14].
- Cash runway limited to Q3 2026 — Cash and equivalents of $3.4M as of June 30, 2026, with runway only into Q3 2026 [sec] [sec_mda · as of 2026-05-14].
- No revenue from ABP-450 — The company has never generated revenue from its sole product candidate and may never become profitable [sec · filed 2025-12-29].
- Dependence on additional financing — Any further development of ABP-450 requires additional funding, which may not be available on reasonable terms [sec_mda · as of 2026-08-12].
What to watch
- Ability to secure additional financing to extend cash runway beyond Q3 2026 [sec_mda · as of 2026-05-14].
- Progress of ABP-450 development under the biosimilar Section 351(k) pathway and any regulatory feedback [sec · filed 2025-12-29].
- Any clinical trial updates or data readouts for ABP-450 in cervical dystonia or other indications [sec · filed 2025-12-29].
- Potential changes in accumulated deficit and net loss trajectory in future filings [sec_mda · as of 2026-05-14].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run AEON Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AEON Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
2.9 months
OCF -$4M · Net income -$1M
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$343K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 181,058 | $178K |
| geode capital management, llc | 87,062 | $86K |
| formidable asset management, llc | 20,024 | $22K |
| xtx topco ltd | 20,424 | $20K |
| jane street group, llc | 16,376 | $16K |
| vanguard fiduciary trust co | 14,702 | $14K |
| blackrock, inc. | 2,834 | $3K |
| steward partners investment advisory, llc | 1,100 | $1K |
| citigroup inc | 742 | $731 |
| wolff wiese magana llc | 567 | $559 |
Showing top 10 of 20 institutional holders of AEON Biopharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 0.6%
- Days to cover
- 2.1
- Shares short
- 144,810
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AEON short interestGovernance
Frequently asked questions
What is the AI investment thesis for AEON Biopharma, Inc.?
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing its sole product candidate, ABP-450, a botulinum toxin formulation for therapeutic indications, and has never generated revenue from product sales.
What is AEON Biopharma, Inc.'s lead drug candidate?
AEON Biopharma, Inc.'s most advanced tracked candidate is abp-450 (Preclinical) for Therapeutic indications for which Botox® is approved (including chronic migraine, cervical dystonia, blepharospasm, strabismus, overactive bladder, adult and pediatric detrusor overactivity, adult and pediatric upper and lower spasticity and axillary hyperhidrosis).
Who is the CEO of AEON Biopharma, Inc.?
Mr. Robert Bancroft is the chief executive officer of AEON Biopharma, Inc. (AEON).
Where is AEON Biopharma, Inc. headquartered?
AEON Biopharma, Inc. (AEON) is headquartered in Irvine, CA, United States.
What therapeutic areas does AEON Biopharma, Inc. focus on?
AEON Biopharma, Inc. develops therapies across Oncology, Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.